Skip to main content

Share story

AI Science

Microsoft releases RetroChimera model for planning chemical synthesis

Microsoft releases RetroChimera model for planning chemical synthesis Image: Primary
Microsoft Research released RetroChimera's implementation and model weights under an MIT license, making the system available through GitHub and Microsoft Foundry. The model plans how to make a target molecule by ranking routes backward from that molecule to simpler starting materials. RetroChimera combines a transformer that can generate unfamiliar reaction patterns with a graph model constrained by templates extracted from training data. A learned voting system merges their ranked proposals. Microsoft says PhD-level chemists in blind tests preferred its individual reaction predictions over those from earlier models and recorded literature reactions, but the company also notes that unconstrained generation can hallucinate.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Microsoft Research and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Security Infrastructure
Security Infrastructure

Ransomware attack halts trading on Nepal Stock Exchange

The Nepal Stock Exchange suspended all Monday trading after ransomware hit infrastructure hosting the trading systems of 72 brokerages. Data Hub detected the attack early that morning and kept affected systems offline while invest...

AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

Novadip raises €10.4 million to complete pivotal bone-graft trial

Belgian regenerative-medicine company Novadip Biosciences has closed a €10.4 million convertible financing led by New Science Ventures. The funding will support completion of an ongoing Phase 3 trial in the United States and Europ...